Balyasny Asset Management L.P. Lowers Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Balyasny Asset Management L.P. reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 32.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 221,391 shares of the company's stock after selling 104,043 shares during the quarter. Balyasny Asset Management L.P. owned 0.55% of Keros Therapeutics worth $3,505,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at $730,000. Algert Global LLC increased its holdings in Keros Therapeutics by 26.0% in the 4th quarter. Algert Global LLC now owns 12,697 shares of the company's stock worth $201,000 after acquiring an additional 2,617 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in Keros Therapeutics in the 4th quarter worth $3,958,000. Darwin Global Management Ltd. raised its position in Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after acquiring an additional 163,403 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its stake in shares of Keros Therapeutics by 37.9% during the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 155,347 shares of the company's stock worth $2,459,000 after purchasing an additional 42,734 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KROS has been the topic of a number of research analyst reports. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Oppenheimer cut their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Scotiabank lowered their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday. Finally, Wedbush reaffirmed a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Stock Performance

Shares of KROS traded up $0.44 during midday trading on Thursday, hitting $14.03. 1,264,944 shares of the stock were exchanged, compared to its average volume of 1,302,345. The stock has a fifty day simple moving average of $12.32 and a 200 day simple moving average of $23.76. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a market cap of $569.83 million, a P/E ratio of -2.69 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same quarter in the prior year, the company earned ($1.21) earnings per share. As a group, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.